Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All nigella sativa studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchNigella SativaNigella Sativa (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial

Said et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.1011522, NCT04981743
Nov 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Recovery, dyspnea 77% Improvement Relative Risk Recovery, NS+D, dyspnea 89% Recovery, cough 80% Recovery, NS+D, cough 77% Recovery, fatigue 85% Recovery, NS+D, fatigue 90% Recovery, smell 85% Recovery, NS+D, smell 67% Recovery, taste 58% Recovery, NS+D, taste 58% Recovery, sore throat 82% Recovery, NS+S 86% Recovery, headache 27% Recovery, NS+D, headache 56% Recovery, diarrhea 80% Recovery, NS+D, diarrhea 90% Viral clearance, day 14 61% Viral clearance, day 7 85% Viral clearance, NS+D, day.. 91% Viral clearance, NS+D, day 7 87% Nigella Sativa  Said et al.  EARLY TREATMENT  RCT Is early treatment with nigella sativa beneficial for COVID-19? RCT 60 patients in Egypt (July - December 2021) Improved recovery (p=0.092) and viral clearance (p=0.081), not sig. c19early.org Said et al., Frontiers in Pharmacology, Nov 2022 Favorsnigella sativa Favorscontrol 0 0.5 1 1.5 2+
12th treatment shown to reduce risk in January 2021
 
*, now with p = 0.00016 from 14 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 81 treatments. c19early.org
120 patient RCT comparing vitamin D, nigella sativa, and combined vitamin D+nigella sativa, showing improved symptom recovery and viral clearance with both vitamin D and nigella sativa, and further improvements with the combination of both. All patients received vitamin C, zinc, and lactoferrin.
Study covers nigella sativa and vitamin D.
risk of no recovery, 77.0% lower, OR 0.23, p = 0.09, treatment 30, control 30, adjusted per study, multivariable, dyspnea, RR approximated with OR.
risk of no recovery, 89.0% lower, OR 0.11, p = 0.01, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, dyspnea, RR approximated with OR.
risk of no recovery, 80.0% lower, OR 0.20, p = 0.003, treatment 30, control 30, adjusted per study, multivariable, cough, RR approximated with OR.
risk of no recovery, 77.0% lower, OR 0.23, p = 0.01, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, cough, RR approximated with OR.
risk of no recovery, 85.0% lower, OR 0.15, p = 0.003, treatment 30, control 30, adjusted per study, multivariable, fatigue, RR approximated with OR.
risk of no recovery, 90.0% lower, OR 0.10, p < 0.001, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, fatigue, RR approximated with OR.
risk of no recovery, 85.0% lower, OR 0.15, p = 0.04, treatment 30, control 30, adjusted per study, multivariable, smell, RR approximated with OR.
risk of no recovery, 67.0% lower, OR 0.33, p = 0.23, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, smell, RR approximated with OR.
risk of no recovery, 58.0% lower, OR 0.42, p = 0.28, treatment 30, control 30, adjusted per study, multivariable, taste, RR approximated with OR.
risk of no recovery, 58.0% lower, OR 0.42, p = 0.28, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, taste, RR approximated with OR.
risk of no recovery, 82.0% lower, OR 0.18, p = 0.05, treatment 30, control 30, sore throat, RR approximated with OR.
risk of no recovery, 86.0% lower, OR 0.14, p = 0.03, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, sore throat, RR approximated with OR.
risk of no recovery, 27.0% lower, OR 0.73, p = 0.62, treatment 30, control 30, headache, RR approximated with OR.
risk of no recovery, 56.0% lower, OR 0.44, p = 0.21, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, headache, RR approximated with OR.
risk of no recovery, 80.0% lower, OR 0.20, p = 0.05, treatment 30, control 30, diarrhea, RR approximated with OR.
risk of no recovery, 90.0% lower, OR 0.10, p = 0.03, treatment 30, control 30, adjusted per study, vitamin D and nigella sativa, multivariable, diarrhea, RR approximated with OR.
risk of no viral clearance, 61.0% lower, OR 0.39, p = 0.08, treatment 30, control 30, day 14, RR approximated with OR.
risk of no viral clearance, 85.0% lower, OR 0.15, p = 0.004, treatment 30, control 30, day 7, RR approximated with OR.
risk of no viral clearance, 91.0% lower, OR 0.09, p < 0.001, treatment 30, control 30, vitamin D and nigella sativa, day 14, RR approximated with OR.
risk of no viral clearance, 87.0% lower, OR 0.13, p = 0.003, treatment 30, control 30, vitamin D and nigella sativa, day 7, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Said et al., 8 Nov 2022, Randomized Controlled Trial, Egypt, peer-reviewed, 5 authors, study period 21 July, 2021 - 30 December, 2021, trial NCT04981743 (history). Contact: nagwa.sabri@pharma.asu.edu.eg.
This PaperNigella SativaAll
The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial
Shimaa A Said, Alsayyed Abdulbaset, Amal A El-Kholy, Osama Besckales, Nagwa A Sabri
Frontiers in Pharmacology, doi:10.3389/fphar.2022.1011522
Background: The coronavirus disease 2019 (COVID-19) is a novel coronavirus that causes severe infection in the respiratory system. Since the immune status plays an essential role in combating COVID-19, herbal medicines, which have an immunomodulatory effect, may help prevent and even treat COVID-19. Nigella sativa is one of the herbal medicines with antiviral and immunomodulatory activities, and its therapeutic effectiveness makes it a promising add-on therapy for COVID-19. In addition, vitamin D3 has an immunomodulatory role, but the effect of therapeutic vitamin D3 supplementation in SARS-CoV-2 infection is still not well-known. Objective: This study aims to investigate the effects of Nigella sativa and vitamin D3 as single supplemental therapies and in combination on viral clearance indicated by a negative polymerase chain reaction and the alleviation of symptoms during the study follow-up duration of 14 days. Patients and Methods: The study design was an open-label randomized controlled clinical trial conducted at the Respiratory Hospital at the Kobry El Qobba Armed Forces Medical Complex. In total, 120 COVID-19 patients with mild to moderate symptoms were randomly assigned to four groups, with thirty patients each, as follows: Group 1 received an oral dose of 900 mg Nigella sativa through 450 mg soft gelatin capsules twice daily for two weeks; Group 2 received 2,000 IU of vitamin D3 through 1000-IU tablets given as two tablets, once daily; Group 3 received 900 mg of Nigella sativa and 2,000 IU of vitamin D3 in the same manner of dosing as in the previous groups; and Group 4 was the control group. All groups received standard therapy for COVID-19 infections and clinical management of COVID-19's clinical symptoms. Results: The Nigella sativa-vitamin D3 combination in addition to the standard therapy for COVID-19 infections significantly contributed to the alleviation of most COVID-19 symptoms: 50% of patients were free of cough after 7 days,
Ethics statement The studies involving human participants were reviewed and approved by the Ethics Committee, Faculty of Pharmacy, Ain Shams University, registered at the Egyptian Ministry of Health (MOH). The study was registered on clinicaltrials.gov (NCT ID: NCT04981743). Author contributions SS and NS formulated the research question. SS performed all the aspects of the clinical trial including acquiring the investigational agents and randomized the patients into treatment groups, data recording, and quality checks. OB and AA followed up patients and monitored for treatment efficacy and safety of investigational agents and reported study outcomes and clinical endpoints to the principal investigator. NS supervised all aspects of this study and provided guidance. AE-K supervised the quality of data. All the authors contributed equally to writing and revising the manuscript. Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abdallah, El-Halawany, Darwish, Algandaby, Mohamed et al., Bio-guided isolation of SARS-CoV-2 main protease inhibitors from medicinal plants: In vitro assay and molecular dynamics, Plants, doi:10.3390/PLANTS11151914
Ahmadian, Biganeh, Panahi, Guest, Jamialahmadi, None
Alshrari, Hudu, Imran, Asdaq, Ali et al., Innovations and development of COVID-19 vaccines: A patent review, J. Infect. Public Health, doi:10.1016/j.jiph.2021.10.021
Anwar, Al Disi, Eid, Anti-hypertensive herbs and their mechanisms of action: Part II, Front. Pharmacol, doi:10.3389/fphar.2016.00050
Asdaq, Rajan, Damodaran, Kamath, Nair et al., None
Ashraf, Ashraf, Akmal, Ashraf, Kalsoom et al., Prophylactic potential of honey and nigella sativa L. Against hospital and community-based SARS-CoV-2 spread: A structured summary of a study protocol for a randomised controlled trial, medRxiv, doi:10.1101/2020.10.30.20217364
Awodele, Oreagba, Fajemirokun, Samuel, Coulidiaty et al., None
Aziz, Son, Cho, Thymoquinone suppresses IRF-3-mediated expression of type I interferons via suppression of TBK1, Int. J. Mol. Sci, doi:10.3390/IJMS19051355
Bilezikian, Bikle, Hewison, Lazaretti-Castro, Formenti et al., Mechanisms in endocrinology: Vitamin D and COVID-19
Boonstra, Barrat, Crain, Heath, Savelkoulo'garra, 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells, J. Immunol, doi:10.4049/jimmunol.167.9.4974
Bouchentouf, Missoum, Identification of compounds from Nigella sativa as new potential inhibitors of 2019 novel coronasvirus (Covid-19): Molecular docking study, doi:10.20944/PREPRINTS202004.0079.V1
Cascella, Rajnik, Aleem, Dulebohn, Napoli, None
Chatterjee, Thakur, Remdesivir and its combination with repurposed drugs as COVID-19 therapeutics, Front. Immunol, doi:10.3389/fimmu.2022.830990
Connelly, Pilot studies, Medsurg Nurs
Erdfelder, Faul, Buchner, Gpower: A general power analysis program, Behav. Res. Methods, Instrum. Comput, doi:10.3758/BF03203630
Fahmy, Sabri, El Hamamsy, El Sawi, Zaki, None
Gandhi, Lynch, Del Rio, Mild or moderate covid-19
Giménez, Sanz, Marón, Ferder, Manucha, Vitamin D-RAAS connection: An integrative standpoint into cardiovascular and neuroinflammatory disorders, Curr. Protein Pept. Sci, doi:10.2174/1389203721666200606220719
Giordo, Zinellu, Eid, Pintus, Therapeutic potential of resveratrol in COVID-19-associated hemostatic disorders, Molecules, doi:10.3390/molecules26040856
Gorman, Tan, Lambert, Scott, Judge, None
Greiller, Martineau, Modulation of the immune response to respiratory viruses by vitamin D, Nutrients, doi:10.3390/nu7064240
Haddadi, Pour, Nigeria ; Hannan, Rahman, Sikder, Black cumin (nigella sativa L.): A comprehensive review on phytochemistry, health benefits, molecular pharmacology, and safety, Nutrients, doi:10.3390/nu13061784
Hart, Vitamin D3 deficiency enhances allergen-induced lymphocyte responses in a mouse model of allergic airway disease, Pediatr. Allergy Immunol
Imran, Khan, Alshammari, Alkhaldi, Alshammari et al., Nigella sativa L. and COVID-19: A glance at the anti-COVID-19 chemical constituents, clinical trials, inventions, and patent literature, Molecules, doi:10.3390/molecules27092750
Jalal, Bakour, Lyoussi, Medicinal plants and zinc: Impact on COVID-19 pandemic, Sci. World J, doi:10.1155/2021/9632034
Khazdair, Ghafari, Sadeghi, Possible therapeutic effects of Nigella sativa and its thymoquinone on COVID-19, Pharm. Biol, doi:10.1080/13880209.2021.1931353
Kim, Jeon, Kang, Kwon, Complementary and alternative medicine for long COVID: Scoping review and bibliometric analysis, Evid. Based. Complement. Altern. Med, doi:10.1155/2022/7303393
Koshak, Koshak, Mobeireek, Badawi, Wali et al., Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial, Complementary Ther. Med, doi:10.1016/J.CTIM.2021.102769
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int. J. Antimicrob. Agents, doi:10.1016/J.IJANTIMICAG.2020.105924
Leaf, Ginde, Vitamin D3 to treat COVID-19: Different disease, same answer, Frontiers in Pharmacology frontiersin
Mahdavi, Namazi, Alizadeh, Farajnia, Effects of nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: A randomized controlled clinical trial, Food Funct, doi:10.1039/c5fo00316d
Malek Mahdavi, A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19, Rev. Med. Virol, doi:10.1002/RMV.2119
Martineau, Forouhi, Elassal, Hassany, Shawky et al., Management protocol for COVID-19 patients MoHP protocol for COVID19 November 2020. Cairo Egypt: Ministry of health and population, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30268-0
Mitchell, Murai, Vitamin-D and COVID-19: Do deficient risk a poorer outcome?, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30183-2
Nigella, Black cumin): A promising natural remedy for wide range of illnesses, Evid. Based. Complement. Altern. Med, doi:10.1155/2019/1528635
Niranjan, Setlur, Karunakaran, Uttarkar, Kumar, None
Phu, Thuan, Nguyen, Posadino, Eid et al., Herbal medicine for slowing aging and aging-associated conditions: Efficacy, mechanisms and safety, Curr. Vasc. Pharmacol, doi:10.2174/1570161117666190715121939
Ramazani, Emami, Tayarani-Najaran, Sahebkar, Tayarani-Najaran, Antiviral plants in view of avicenna's the canon of medicine and modern medicine against common cold, Adv. Exp. Med. Biol, doi:10.1007/978-3-030-73234-9_7
Raslan, Ms, Ar, Sabri, Microbiota in the era of COVID-19. Correlation and benefits, Act. Scie. Pharma, doi:10.31080/ASPS.2022.06.0883
Raslan, Ms, Ar, Sabri, The significance of COVID-19 vaccine booster dose. A comparative review, Act. Scie. Pharma, doi:10.31080/asps.2022.06.0872
Rastogi, Bhansali, Khare, Suri, Yaddanapudi et al., Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebo-controlled
Rostami, Gharibi, Yaghoobi, Nokhodian, Shoaei et al., Herbal medicines as potential inhibitors of SARS-CoV-2 infection, Curr. Pharm. Des, doi:10.2174/1381612828666220802121014
Safdari, Shakeri, Mohammadi, Bibak, Alesheikh et al., Role of herbal medicines in the management of brain injury, Adv. Exp. Med. Biol, doi:10.1016/j.steroids.2022.109102
Sahebkar, Disi, Anwar, Eid, Resveratrol as a probable multiheaded treatment approach for COVID-19, Adv. Exp. Med. Biol, doi:10.3389/fphar.2015.00323
Shaito, Thuan, Phu, Nguyen, Hasan et al., Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and safety, Front. Pharmacol, doi:10.3389/fphar.2020.00422
Shirvani, Rostamkhani, Arabzadeh, Mohammadi, Mohammadi et al., Potential role of Nigella sativa supplementation with physical activity in prophylaxis and treatment of COVID-19: A contemporary review, Cochrane Database Syst. Rev, doi:10.1002/14651858.CD015043
Skariyachan, Nugraha, Ridwansyah, Ghozali, Khairani et al., Traditional herbal medicine candidates as complementary treatments for COVID-19: A review of their mechanisms, pros and cons. Evidence-based Complementary, Struct. Chem, doi:10.1155/2020/2560645
Ullah, Munir, Al-Sehemi, Muhammad, Haq et al., Identification of phytochemical inhibitors of SARS-CoV-2 protease 3CLpro from selected medicinal plants as per molecular docking, bond energies and amino acid binding energies, Saudi J. Biol. Sci, doi:10.1016/j.sjbs.2022.03.024
Wehbe, Hammoud, Soudani, Zaraket, El-Yazbi et al., Molecular insights into SARS COV-2 interaction with cardiovascular disease: Role of RAAS and MAPK signaling, Front. Pharmacol, doi:10.3389/fphar.2020.00836
Wehbe, Wehbe, Iratni, Pintus, Zaraket et al., World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects, JAMA -J. Am. Med. Assoc, doi:10.1001/jama.2013.281053
Weir, Thenappan, Bhargava, Chen, Does vitamin D deficiency increase the severity of COVID-19?, Clin. Med, doi:10.7861/CLINMED.2020-0301
Yimer, Tuem, Karim, Ur-Rehman, Anwar, None
Younis, Zareef, Al Hassan, Bitar, Eid et al., Hydroxychloroquine in COVID-19 patients: Pros and cons, Front. Pharmacol, doi:10.3389/fphar.2020.597985
Zahedipour, Hosseini, Henney, Barreto, Sahebkar, Phytochemicals as inhibitors of tumor necrosis factor alpha and neuroinflammatory responses in neurodegenerative diseases, Frontiers in Pharmacology frontiersin
{ 'indexed': {'date-parts': [[2022, 11, 8]], 'date-time': '2022-11-08T07:41:11Z', 'timestamp': 1667893271435}, 'reference-count': 61, 'publisher': 'Frontiers Media SA', 'license': [ { 'start': { 'date-parts': [[2022, 11, 8]], 'date-time': '2022-11-08T00:00:00Z', 'timestamp': 1667865600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': ['frontiersin.org'], 'crossmark-restriction': True}, 'abstract': '<jats:p><jats:bold>Background:</jats:bold> The coronavirus disease 2019 (COVID-19) is a novel ' 'coronavirus that causes severe infection in the respiratory system. Since the immune status ' 'plays an essential role in combating COVID-19, herbal medicines, which have an ' 'immunomodulatory effect, may help prevent and even treat COVID-19. ' '<jats:italic>Nigella</jats:italic><jats:italic>sativa</jats:italic> is one of the herbal ' 'medicines with antiviral and immunomodulatory activities, and its therapeutic effectiveness ' 'makes it a promising add-on therapy for COVID-19. In addition, vitamin D3 has an ' 'immunomodulatory role, but the effect of therapeutic vitamin D3 supplementation in SARS-CoV-2 ' 'infection is still not well-known.</jats:p><jats:p><jats:bold>Objective:</jats:bold> This ' 'study aims to investigate the effects of <jats:italic>Nigella sativa</jats:italic> and ' 'vitamin D3 as single supplemental therapies and in combination on viral clearance indicated ' 'by a negative polymerase chain reaction and the alleviation of symptoms during the study ' 'follow-up duration of 14\xa0days.</jats:p><jats:p><jats:bold>Patients and ' 'Methods:</jats:bold> The study design was an open-label randomized controlled clinical trial ' 'conducted at the Respiratory Hospital at the Kobry El Qobba Armed Forces Medical Complex. In ' 'total, 120 COVID-19 patients with mild to moderate symptoms were randomly assigned to four ' 'groups, with thirty patients each, as follows: Group 1 received an oral dose of 900\xa0mg ' '<jats:italic>Nigella sativa</jats:italic> through 450\xa0mg soft gelatin capsules twice daily ' 'for two weeks; Group 2 received 2,000 IU of vitamin D3 through 1000-IU tablets given as two ' 'tablets, once daily; Group 3 received 900\xa0mg of <jats:italic>Nigella sativa</jats:italic> ' 'and 2,000 IU of vitamin D3 in the same manner of dosing as in the previous groups; and Group ' '4 was the control group. All groups received standard therapy for COVID-19 infections and ' 'clinical management of COVID-19’s clinical ' 'symptoms.</jats:p><jats:p><jats:bold>Results:</jats:bold> The <jats:italic>Nigella ' 'sativa</jats:italic>–vitamin D3 combination in addition to the standard therapy for COVID-19 ' 'infections significantly contributed to the alleviation of most COVID-19 symptoms: 50% of ' 'patients were free of cough after 7\xa0days, 70% showed an absence of fatigue after 4\xa0' 'days, 80% had no headache after 5\xa0days, 90% were free of rhinorrhea after 7\xa0days, and ' '86.7% of the patients had no dyspnea after 7\xa0days. Moreover, patients in the four studied ' 'groups showed a reduced median temperature after 3\xa0days of treatment. Negative results of ' 'the polymerase chain reaction (PCR) test recorded on the 7th and 14th\xa0day of therapy were ' 'superior in the <jats:italic>Nigella sativa</jats:italic> and vitamin D3 combination arm ' 'compared to those of the other studied arms where the value of the odds ratio (OR) on the ' '7th\xa0day was 0.13 with 95% CI: 0.03–0.45 and that of the 14th day was 0.09 with 95% CI: ' '0.02–0.3.</jats:p><jats:p><jats:bold>Conclusion:</jats:bold> The results of this study showed ' 'a promising therapeutic benefit of the administration of <jats:italic>Nigella ' 'sativa</jats:italic> and vitamin D3 combination in COVID-19 patients with mild to moderate ' 'symptoms. Additionally, the remarkable viral clearance in a short time interval and reduction ' 'in the severity and progression of symptoms recommended the use of this combination as an ' 'add-on therapy for the management of COVID-19 patients.</jats:p><jats:p><jats:bold>Clinical ' 'Trial Registration:</jats:bold><jats:ext-link>ClinicalTrials.gov</jats:ext-link>, Identifier: ' 'NCT04981743.</jats:p>', 'DOI': '10.3389/fphar.2022.1011522', 'type': 'journal-article', 'created': {'date-parts': [[2022, 11, 8]], 'date-time': '2022-11-08T07:02:23Z', 'timestamp': 1667890943000}, 'update-policy': 'http://dx.doi.org/10.3389/crossmark-policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 ' 'patients: A randomized controlled clinical trial', 'prefix': '10.3389', 'volume': '13', 'author': [ {'given': 'Shimaa A.', 'family': 'Said', 'sequence': 'first', 'affiliation': []}, {'given': 'Alsayyed', 'family': 'Abdulbaset', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amal A.', 'family': 'El-Kholy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Osama', 'family': 'Besckales', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nagwa A.', 'family': 'Sabri', 'sequence': 'additional', 'affiliation': []}], 'member': '1965', 'published-online': {'date-parts': [[2022, 11, 8]]}, 'reference': [ { 'key': 'B1', 'doi-asserted-by': 'publisher', 'first-page': '1914', 'DOI': '10.3390/PLANTS11151914', 'article-title': 'Bio-guided isolation of SARS-CoV-2 main protease inhibitors from ' 'medicinal plants: In vitro assay and molecular dynamics', 'volume': '11', 'author': 'Abdallah', 'year': '2022', 'journal-title': 'Plants'}, { 'key': 'B2', 'doi-asserted-by': 'publisher', 'first-page': '441', 'DOI': '10.1007/978-3-030-73234-9_29', 'article-title': 'Resveratrol as a probable multiheaded treatment approach for COVID-19', 'volume': '1328', 'author': 'Ahmadian', 'year': '2021', 'journal-title': 'Adv. Exp. Med. Biol.'}, { 'key': 'B3', 'doi-asserted-by': 'publisher', 'first-page': '323', 'DOI': '10.3389/fphar.2015.00323', 'article-title': 'Anti-hypertensive herbs and their mechanisms of action: Part I', 'volume': '19', 'author': 'Al Disi', 'year': '2016', 'journal-title': 'Front. Pharmacol.'}, { 'key': 'B4', 'doi-asserted-by': 'publisher', 'first-page': '123', 'DOI': '10.1016/j.jiph.2021.10.021', 'article-title': 'Innovations and development of COVID-19 vaccines: A patent review', 'volume': '15', 'author': 'Alshrari', 'year': '2022', 'journal-title': 'J. Infect. Public Health'}, { 'key': 'B5', 'doi-asserted-by': 'publisher', 'first-page': '50', 'DOI': '10.3389/fphar.2016.00050', 'article-title': 'Anti-hypertensive herbs and their mechanisms of action: Part II', 'volume': '7', 'author': 'Anwar', 'year': '2016', 'journal-title': 'Front. Pharmacol.'}, { 'key': 'B6', 'doi-asserted-by': 'publisher', 'first-page': '1308', 'DOI': '10.3390/antibiotics10111308', 'article-title': 'Identifying mucormycosis severity in Indian COVID-19 patients: A ' 'nano-based diagnosis and the necessity for critical therapeutic ' 'intervention', 'volume': '10', 'author': 'Asdaq', 'year': '2021', 'journal-title': 'Antibiotics'}, { 'key': 'B7', 'doi-asserted-by': 'publisher', 'first-page': '618', 'DOI': '10.1186/s13063-021-05510-3', 'article-title': 'Prophylactic potential of honey and nigella sativa L. Against hospital ' 'and community-based SARS-CoV-2 spread: A structured summary of a study ' 'protocol for a randomised controlled trial', 'volume': '22', 'author': 'Ashraf', 'year': '2021', 'journal-title': 'Trials'}, { 'key': 'B8', 'doi-asserted-by': 'publisher', 'article-title': 'Efficacy of honey and nigella sativa against COVID-19: HNS-COVID-PK ' 'trial', 'author': 'Ashraf', 'year': '2020', 'journal-title': 'A multi-center placebo-controlled randomized clinical trial', 'DOI': '10.1101/2020.10.30.20217364'}, { 'key': 'B9', 'first-page': '1', 'article-title': 'Herbal medicines use : Remedies or risks', 'volume': '29', 'author': 'Awodele', 'year': '2018', 'journal-title': 'West Afr. J. Pharm.'}, { 'key': 'B10', 'doi-asserted-by': 'publisher', 'first-page': '1355', 'DOI': '10.3390/IJMS19051355', 'article-title': 'Thymoquinone suppresses IRF-3-mediated expression of type I interferons ' 'via suppression of TBK1', 'volume': '19', 'author': 'Aziz', 'year': '2018', 'journal-title': 'Int. J. Mol. Sci.'}, { 'key': 'B11', 'doi-asserted-by': 'publisher', 'first-page': 'R133', 'DOI': '10.1530/EJE-20-0665', 'article-title': 'Mechanisms in endocrinology: Vitamin D and COVID-19', 'volume': '183', 'author': 'Bilezikian', 'year': '2020', 'journal-title': 'Eur. J. Endocrinol.'}, { 'key': 'B12', 'doi-asserted-by': 'publisher', 'first-page': '4974', 'DOI': '10.4049/jimmunol.167.9.4974', 'article-title': '1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T ' 'cells to enhance the development of Th2 cells', 'volume': '167', 'author': 'Boonstra', 'year': '2001', 'journal-title': 'J. Immunol.'}, { 'key': 'B13', 'doi-asserted-by': 'publisher', 'article-title': 'Identification of compounds from Nigella sativa as new potential ' 'inhibitors of 2019 novel coronasvirus (Covid-19): Molecular docking ' 'study', 'author': 'Bouchentouf', 'year': '2020', 'DOI': '10.20944/PREPRINTS202004.0079.V1'}, { 'key': 'B14', 'unstructured': 'Features, evaluation, and treatment of coronavirus (COVID-19)\n' ' CascellaM.\n' ' RajnikM.\n' ' AleemA.\n' ' DulebohnS. C.\n' ' Di NapoliR.\n' ' 2022'}, { 'key': 'B15', 'doi-asserted-by': 'publisher', 'first-page': '830990', 'DOI': '10.3389/fimmu.2022.830990', 'article-title': 'Remdesivir and its combination with repurposed drugs as COVID-19 ' 'therapeutics', 'volume': '13', 'author': 'Chatterjee', 'year': '2022', 'journal-title': 'Front. Immunol.'}, { 'key': 'B16', 'first-page': '411', 'article-title': 'Pilot studies', 'volume': '17', 'author': 'Connelly', 'year': '2008', 'journal-title': 'Medsurg Nurs.'}, { 'key': 'B17', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.3758/BF03203630', 'article-title': 'Gpower: A general power analysis program', 'volume': '28', 'author': 'Erdfelder', 'year': '1996', 'journal-title': 'Behav. Res. Methods, Instrum. Comput.'}, { 'key': 'B18', 'doi-asserted-by': 'publisher', 'first-page': '1043', 'DOI': '10.13040/IJPSR.0975-8232.7(3).1043-49', 'article-title': 'Vitamin D intake and sun exposure in autistic children', 'volume': '7', 'author': 'Fahmy', 'year': '2016', 'journal-title': 'Int. J. Pharm. Sci. Res.'}, { 'key': 'B19', 'doi-asserted-by': 'publisher', 'first-page': '1757', 'DOI': '10.1056/NEJMCP2009249', 'article-title': 'Mild or moderate covid-19', 'volume': '383', 'author': 'Gandhi', 'year': '2020', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'B20', 'doi-asserted-by': 'publisher', 'first-page': '948', 'DOI': '10.2174/1389203721666200606220719', 'article-title': 'Vitamin D-RAAS connection: An integrative standpoint into ' 'cardiovascular and neuroinflammatory disorders', 'volume': '21', 'author': 'Giménez', 'year': '2020', 'journal-title': 'Curr. Protein Pept. Sci.'}, { 'key': 'B21', 'doi-asserted-by': 'publisher', 'first-page': '856', 'DOI': '10.3390/molecules26040856', 'article-title': 'Therapeutic potential of resveratrol in COVID-19-associated hemostatic ' 'disorders', 'volume': '26', 'author': 'Giordo', 'year': '2021', 'journal-title': 'Molecules'}, { 'key': 'B22', 'doi-asserted-by': 'publisher', 'first-page': '83', 'DOI': '10.1111/J.1399-3038.2011.01146.X', 'article-title': 'Vitamin D3 deficiency enhances allergen-induced lymphocyte responses in ' 'a mouse model of allergic airway disease', 'volume': '23', 'author': 'Gorman', 'year': '2012', 'journal-title': 'Pediatr. Allergy Immunol.'}, { 'key': 'B23', 'doi-asserted-by': 'publisher', 'first-page': '4240', 'DOI': '10.3390/nu7064240', 'article-title': 'Modulation of the immune response to respiratory viruses by vitamin D', 'volume': '7', 'author': 'Greiller', 'year': '2015', 'journal-title': 'Nutrients'}, { 'key': 'B24', 'volume-title': 'IRCT approved: International and national patent: Herbal medicine for ' 'the treatment of COVID-19/PCT: WO2022009236A1/139950140003003167', 'author': 'Haddadi', 'year': '2022'}, { 'key': 'B25', 'doi-asserted-by': 'publisher', 'first-page': '1784', 'DOI': '10.3390/nu13061784', 'article-title': 'Black cumin (nigella sativa L.): A comprehensive review on ' 'phytochemistry, health benefits, molecular pharmacology, and safety', 'volume': '13', 'author': 'Hannan', 'year': '2021', 'journal-title': 'Nutrients'}, { 'key': 'B26', 'doi-asserted-by': 'publisher', 'first-page': '2750', 'DOI': '10.3390/molecules27092750', 'article-title': 'Nigella sativa L. and COVID-19: A glance at the anti-COVID-19 chemical ' 'constituents, clinical trials, inventions, and patent literature', 'volume': '27', 'author': 'Imran', 'year': '2022', 'journal-title': 'Molecules'}, { 'key': 'B27', 'doi-asserted-by': 'publisher', 'first-page': '9632034', 'DOI': '10.1155/2021/9632034', 'article-title': 'Medicinal plants and zinc: Impact on COVID-19 pandemic', 'volume': '2021', 'author': 'Jalal', 'year': '2021', 'journal-title': 'Sci. World J.'}, { 'key': 'B28', 'doi-asserted-by': 'publisher', 'first-page': 'E107', 'DOI': '10.7861/CLINMED.2020-0301', 'article-title': 'Does vitamin D deficiency increase the severity of COVID-19?', 'volume': '20', 'author': 'Kenneth Weir', 'year': '2020', 'journal-title': 'Clin. Med.'}, { 'key': 'B29', 'doi-asserted-by': 'publisher', 'first-page': '696', 'DOI': '10.1080/13880209.2021.1931353', 'article-title': 'Possible therapeutic effects of Nigella sativa and its thymoquinone on ' 'COVID-19', 'volume': '59', 'author': 'Khazdair', 'year': '2021', 'journal-title': 'Pharm. Biol.'}, { 'key': 'B30', 'doi-asserted-by': 'publisher', 'first-page': '7303393', 'DOI': '10.1155/2022/7303393', 'article-title': 'Complementary and alternative medicine for long COVID: Scoping review ' 'and bibliometric analysis', 'volume': '2022', 'author': 'Kim', 'year': '2022', 'journal-title': 'Evid. Based. Complement. Altern. Med.'}, { 'key': 'B31', 'doi-asserted-by': 'publisher', 'first-page': '102769', 'DOI': '10.1016/J.CTIM.2021.102769', 'article-title': 'Nigella sativa for the treatment of COVID-19: An open-label randomized ' 'controlled clinical trial', 'volume': '61', 'author': 'Koshak', 'year': '2021', 'journal-title': 'Complementary Ther. Med.'}, { 'key': 'B32', 'doi-asserted-by': 'publisher', 'first-page': '105924', 'DOI': '10.1016/J.IJANTIMICAG.2020.105924', 'article-title': 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ' 'coronavirus disease-2019 (COVID-19): The epidemic and the challenges', 'volume': '55', 'author': 'Lai', 'year': '2020', 'journal-title': 'Int. J. Antimicrob. Agents'}, { 'key': 'B33', 'doi-asserted-by': 'publisher', 'first-page': '1047', 'DOI': '10.1001/JAMA.2020.26850', 'article-title': 'Vitamin D3 to treat COVID-19: Different disease, same answer', 'volume': '325', 'author': 'Leaf', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': 'B34', 'doi-asserted-by': 'publisher', 'first-page': '2041', 'DOI': '10.1039/c5fo00316d', 'article-title': 'Effects of nigella sativa oil with a low-calorie diet on ' 'cardiometabolic risk factors in obese women: A randomized controlled ' 'clinical trial', 'volume': '6', 'author': 'Mahdavi', 'year': '2015', 'journal-title': 'Food Funct.'}, { 'key': 'B35', 'doi-asserted-by': 'publisher', 'first-page': 'e2119', 'DOI': '10.1002/RMV.2119', 'article-title': 'A brief review of interplay between vitamin D and ' 'angiotensin‐converting enzyme 2: Implications for a potential treatment ' 'for COVID‐19', 'volume': '30', 'author': 'Malek Mahdavi', 'year': '2020', 'journal-title': 'Rev. Med. Virol.'}, { 'key': 'B70', 'doi-asserted-by': 'publisher', 'first-page': '735', 'DOI': '10.1016/S2213-8587(20)30268-0', 'article-title': 'Vitamin D for COVID-19: A case to answer?', 'volume': '8', 'author': 'Martineau', 'year': '2020', 'journal-title': 'Lancet Diabetes Endocrinol'}, { 'key': 'B36', 'volume-title': 'Management protocol for COVID-19 patients MoHP protocol for COVID19 ' 'November 2020', 'author': 'Masoud', 'year': '2020'}, { 'key': 'B37', 'doi-asserted-by': 'publisher', 'first-page': 'e2019722', 'DOI': '10.1001/JAMANETWORKOPEN.2020.19722', 'article-title': 'Association of vitamin D status and other clinical characteristics with ' 'COVID-19 test results', 'volume': '3', 'author': 'Meltzer', 'year': '2020', 'journal-title': 'JAMA Netw. Open'}, { 'key': 'B71', 'doi-asserted-by': 'publisher', 'first-page': '570', 'DOI': '10.1016/S2213-8587(20)30183-2', 'article-title': 'Vitamin-D and COVID-19: Do deficient risk a poorer outcome?', 'volume': '8', 'author': 'Mitchell', 'year': '2020', 'journal-title': 'Lancet Diabetes Endocrinol.'}, { 'key': 'B38', 'volume-title': 'SPECIFIC AIMS Fitra30 COVID-19 protocol', 'author': 'Muhammad', 'year': '2021'}, { 'key': 'B39', 'doi-asserted-by': 'publisher', 'first-page': '1053', 'DOI': '10.1001/JAMA.2020.26848', 'article-title': 'Effect of a single high dose of vitamin D3 on hospital length of stay ' 'in patients with moderate to severe COVID-19: A randomized clinical ' 'trial', 'volume': '325', 'author': 'Murai', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': 'B40', 'doi-asserted-by': 'publisher', 'first-page': '1585', 'DOI': '10.1007/s11224-022-02020-z', 'article-title': 'Scope of repurposed drugs against the potential targets of the latest ' 'variants of SARS-CoV-2', 'volume': '33', 'author': 'Niranjan', 'year': '2022', 'journal-title': 'Struct. Chem.'}, { 'key': 'B41', 'doi-asserted-by': 'publisher', 'first-page': '12', 'DOI': '10.1155/2020/2560645', 'article-title': 'Traditional herbal medicine candidates as complementary treatments for ' 'COVID-19: A review of their mechanisms, pros and cons', 'volume': '2020', 'author': 'Nugraha', 'year': '2020', 'journal-title': 'Evidence-based Complementary Altern. Med.'}, { 'key': 'B42', 'doi-asserted-by': 'publisher', 'first-page': '369', 'DOI': '10.2174/1570161117666190715121939', 'article-title': 'Herbal medicine for slowing aging and aging-associated conditions: ' 'Efficacy, mechanisms and safety', 'volume': '18', 'author': 'Phu', 'year': '2020', 'journal-title': 'Curr. Vasc. Pharmacol.'}, { 'key': 'B43', 'doi-asserted-by': 'publisher', 'first-page': '99', 'DOI': '10.1007/978-3-030-73234-9_7', 'article-title': "Antiviral plants in view of avicenna's the canon of medicine and modern " 'medicine against common cold', 'volume': '1328', 'author': 'Ramazani', 'year': '2021', 'journal-title': 'Adv. Exp. Med. Biol.'}, { 'key': 'B44', 'doi-asserted-by': 'publisher', 'first-page': '22', 'DOI': '10.31080/ASPS.2022.06.0883', 'article-title': 'Microbiota in the era of COVID-19. Correlation and benefits', 'volume': '6', 'author': 'Raslan', 'year': '', 'journal-title': 'Act. Scie. Pharma.'}, { 'key': 'B45', 'doi-asserted-by': 'publisher', 'first-page': '03', 'DOI': '10.31080/asps.2022.06.0872', 'article-title': 'The significance of COVID-19 vaccine booster dose. A comparative review', 'volume': '6', 'author': 'Raslan', 'year': '', 'journal-title': 'Act. Scie. Pharma.'}, { 'key': 'B46', 'doi-asserted-by': 'publisher', 'first-page': '87', 'DOI': '10.1136/POSTGRADMEDJ-2020-139065', 'article-title': 'Short term, high-dose vitamin D supplementation for COVID-19 disease: A ' 'randomised, placebo-controlled, study (SHADE study)', 'volume': '98', 'author': 'Rastogi', 'year': '2022', 'journal-title': 'Postgrad. Med. J.'}, { 'key': 'B47', 'doi-asserted-by': 'publisher', 'first-page': '2375', 'DOI': '10.2174/1381612828666220802121014', 'article-title': 'Herbal medicines as potential inhibitors of SARS-CoV-2 infection', 'volume': '2', 'author': 'Rostami', 'year': '2022', 'journal-title': 'Curr. Pharm. Des.'}, { 'key': 'B48', 'doi-asserted-by': 'publisher', 'first-page': '287', 'DOI': '10.1007/978-3-030-73234-9_19', 'article-title': 'Role of herbal medicines in the management of brain injury', 'volume': '1328', 'author': 'Safdari', 'year': '2021', 'journal-title': 'Adv. Exp. Med. Biol.'}, { 'key': 'B49', 'doi-asserted-by': 'publisher', 'first-page': '109102', 'DOI': '10.1016/j.steroids.2022.109102', 'article-title': 'Corticosteroids: A boon or bane for COVID-19 patients?', 'volume': '24', 'author': 'Sen', 'year': '2022', 'journal-title': 'Steroids'}, { 'key': 'B50', 'doi-asserted-by': 'publisher', 'first-page': '422', 'DOI': '10.3389/fphar.2020.00422', 'article-title': 'Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and ' 'safety', 'volume': '11', 'author': 'Shaito', 'year': '2020', 'journal-title': 'Front. Pharmacol.'}, { 'key': 'B51', 'doi-asserted-by': 'publisher', 'first-page': '849', 'DOI': '10.1007/s11332-021-00787-y', 'article-title': 'Potential role of Nigella sativa supplementation with physical activity ' 'in prophylaxis and treatment of COVID-19: A contemporary review', 'volume': '17', 'author': 'Shirvani', 'year': '2021', 'journal-title': 'Sport Sci. Health'}, { 'key': 'B52', 'doi-asserted-by': 'publisher', 'first-page': 'CD015043', 'DOI': '10.1002/14651858.CD015043', 'article-title': 'Vitamin D supplementation for the treatment of COVID-19: A living ' 'systematic review', 'volume': '5', 'author': 'Stroehlein', 'year': '2021', 'journal-title': 'Cochrane Database Syst. Rev.'}, { 'key': 'B53', 'doi-asserted-by': 'publisher', 'first-page': '103274', 'DOI': '10.1016/j.sjbs.2022.03.024', 'article-title': 'Identification of phytochemical inhibitors of SARS-CoV-2 protease ' '3CLpro from selected medicinal plants as per molecular docking, bond ' 'energies and amino acid binding energies', 'volume': '29', 'author': 'Ullah', 'year': '2022', 'journal-title': 'Saudi J. Biol. Sci.'}, { 'key': 'B54', 'doi-asserted-by': 'publisher', 'first-page': '836', 'DOI': '10.3389/fphar.2020.00836', 'article-title': 'Molecular insights into SARS COV-2 interaction with cardiovascular ' 'disease: Role of RAAS and MAPK signaling', 'volume': '3', 'author': 'Wehbe', 'year': '2020', 'journal-title': 'Front. Pharmacol.'}, { 'key': 'B55', 'doi-asserted-by': 'publisher', 'first-page': '663586', 'DOI': '10.3389/fimmu.2021.663586', 'article-title': 'Repurposing ivermectin for COVID-19: Molecular aspects and therapeutic ' 'possibilities', 'volume': '30', 'author': 'Wehbe', 'year': '2021', 'journal-title': 'Front. Immunol.'}, { 'key': 'B56', 'doi-asserted-by': 'publisher', 'first-page': '2191', 'DOI': '10.1001/jama.2013.281053', 'article-title': 'World Medical Association declaration of Helsinki: Ethical principles ' 'for medical research involving human subjects', 'volume': '310', 'year': '2013', 'journal-title': 'JAMA - J. Am. Med. Assoc.'}, { 'key': 'B57', 'doi-asserted-by': 'publisher', 'first-page': '1528635', 'DOI': '10.1155/2019/1528635', 'article-title': 'Nigella sativa L. (Black cumin): A promising natural remedy for wide ' 'range of illnesses', 'volume': '2019', 'author': 'Yimer', 'year': '2019', 'journal-title': 'Evid. Based. Complement. Altern. Med.'}, { 'key': 'B58', 'doi-asserted-by': 'publisher', 'first-page': '597985', 'DOI': '10.3389/fphar.2020.597985', 'article-title': 'Hydroxychloroquine in COVID-19 patients: Pros and cons', 'volume': '19', 'author': 'Younis', 'year': '2020', 'journal-title': 'Front. Pharmacol.'}, { 'key': 'B59', 'doi-asserted-by': 'publisher', 'first-page': '1675', 'DOI': '10.4103/1673-5374.332128', 'article-title': 'Phytochemicals as inhibitors of tumor necrosis factor alpha and ' 'neuroinflammatory responses in neurodegenerative diseases', 'volume': '17', 'author': 'Zahedipour', 'year': '2022', 'journal-title': 'Neural Regen. Res.'}], 'container-title': 'Frontiers in Pharmacology', 'original-title': [], 'link': [ { 'URL': 'https://www.frontiersin.org/articles/10.3389/fphar.2022.1011522/full', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 11, 8]], 'date-time': '2022-11-08T07:02:31Z', 'timestamp': 1667890951000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.frontiersin.org/articles/10.3389/fphar.2022.1011522/full'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 11, 8]]}, 'references-count': 61, 'alternative-id': ['10.3389/fphar.2022.1011522'], 'URL': 'http://dx.doi.org/10.3389/fphar.2022.1011522', 'relation': {}, 'ISSN': ['1663-9812'], 'subject': ['Pharmacology (medical)', 'Pharmacology'], 'container-title-short': 'Front. Pharmacol.', 'published': {'date-parts': [[2022, 11, 8]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit